サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1363049

遺伝性血管性浮腫治療薬の市場規模、シェア、動向分析レポート：治療別、投与経路別、最終用途別、地域別、セグメント予測、2023年～2030年

Hereditary Angioedema Therapeutics Market Size, Share & Trends Analysis Report By Treatment (Bradykinin B2 Receptor Antagonist, C1-Esterase Inhibitor), By Route of Administration, By End Use, By Region, And Segment Forecasts, 2023 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 100 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
遺伝性血管性浮腫治療薬の市場規模、シェア、動向分析レポート：治療別、投与経路別、最終用途別、地域別、セグメント予測、2023年～2030年
出版日: 2023年09月15日
発行: Grand View Research
ページ情報: 英文 100 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

遺伝性血管性浮腫治療薬市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の遺伝性血管性浮腫治療薬市場規模は2030年までに58億米ドルに達すると予測され、2023年から2030年までのCAGRは7.4%です。

患者やヘルスケアプロバイダーの間で遺伝性血管性浮腫（HAE）に関する認知度を向上させるための国際的な患者団体によるイニシアチブの高まりは、市場にとってインパクトの大きい促進要因になりそうです。

HAE International（HAEi）に加盟する患者支援団体は、遺伝性血管性浮腫の認知度を高めるため、印刷物とソーシャルメディアの両方を通じたキャンペーンに注力しています。HAEiはまた、患者の意識レベルを向上させるために家族検査ツールを導入しており、これは正確な診断と最適な医療を提供するのに役立つと思われます。CSL Limited、Pharming Group N.V.、Shire Plc.などの製薬会社やバイオテクノロジー企業も、HAEの治療法の開発に携わっており、遺伝性血管性浮腫の効果的な診断プロセスや治療法を確立するために、遺伝性血管性浮腫のコミュニティと協力しています。

遺伝性血管性浮腫の発作を管理するための新しい治療法を開発するために、世界中のさまざまな国の大学が互いに協力しています。例えば、2018年には、欧州、オーストラリア、カナダの26の大学が、この疾患の予防のための新規経口療法を開発するための国際共同研究を行っています。

新しい治療法への患者のアクセスを改善するために各国が実施している対策は、HAEの迅速な薬剤審査と承認を促進するための規制ガイドラインの修正とともに、市場成長に寄与すると予想されます。例えば、2018年7月、中国の国家衛生委員会（NHC）と国家薬品監督管理局（SDA）は、現在国内で治療法が提供されていない希少疾患の治療法について、製薬メーカーが新薬承認申請（NDA）を行うことを許可しました。この決定により、医薬品メーカーは新薬承認申請時に中国国外の臨床試験データを使用することができるようになっています。

遺伝性血管性浮腫治療薬市場レポート・ハイライト

  • C1-エステラーゼ阻害剤セグメントは、HAEのオンデマンド治療および予防的治療における製品の高い使用率により、2022年に最大のシェアを占めました。
  • オンデマンド治療が市場の圧倒的シェアを占め、予測期間中に有利な成長が見込まれます。新たな地域での製品発売が期待され、このセグメントの主要な促進要因となりそうです。
  • 北米は、2022年の売上高で遺伝性血管性浮腫治療薬市場全体を支配しました。この疾患の症例数の増加、有利な政府プログラム、患者間の認識レベルの向上、高度に専門化した医療従事者の存在が、この地域市場の主要シェアに寄与している要因です。
  • アジア太平洋地域は、ヘルスケア・インフラの改善とアンメット・メディカル・ニーズの高さから、予測期間中に有利な成長を記録すると予想されます。さらに、この疾患の治療のための新しい治療法の発売は、この地域の市場成長を促進すると思われます。
  • 主なプレーヤーとしては、Ionis Pharmaceuticals, Inc.、BioCryst Pharmaceuticals, Inc.、Pharming Group N.V.、CSL Limited、Shire plc、Adverum Biotechnologies, Inc.、Attune Pharmaceuticals, Inc.、KalVista Pharmaceuticals, Inc.などが挙げられます。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 遺伝性血管性浮腫治療薬市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 普及と成長の見通しマッピング
  • 市場力学
    • 市場促進要因の分析
    • 市場抑制要因分析
  • 遺伝性血管性浮腫治療薬市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析

第4章 遺伝性血管性浮腫治療薬市場：治療別推定・動向分析

  • 遺伝性血管性浮腫治療薬市場：重要なポイント
  • 遺伝性血管性浮腫治療薬市場：動向と市場シェア分析、2022年および2030年
  • C1-エステラーゼ阻害剤
  • ブラジキニンB2受容体拮抗薬
  • カリクレイン阻害剤
  • その他

第5章 遺伝性血管性浮腫治療薬市場：最終用途別推定・動向分析

  • 遺伝性血管性浮腫治療薬市場：重要なポイント
  • 遺伝性血管性浮腫治療薬市場：動向と市場シェア分析、2022年および2030年
  • 予防
  • オンデマンド

第6章 遺伝性血管性浮腫治療薬市場：投与経路別推定・動向分析

  • 遺伝性血管性浮腫治療薬市場：重要なポイント
  • 遺伝性血管性浮腫治療薬市場：動向と市場シェア分析、2022年および2030年
  • 静脈内
  • 皮下
  • 経口

第7章 遺伝性血管性浮腫治療薬市場：地域別推定・動向分析

  • 地域別の展望
  • 地域別の遺伝性血管性浮腫治療薬市場：重要なポイント
  • 北米
    • 市場推計・予測、2018～2030年
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • スウェーデン
    • ノルウェー
    • デンマーク
  • アジア太平洋地域
    • 日本
    • 中国
    • インド
    • オーストラリア
    • タイ
    • 韓国
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東・アフリカ
    • サウジアラビア
    • 南アフリカ
    • アラブ首長国連邦
    • クウェート

第8章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 市場参入企業の分類
    • BioCryst Pharmaceuticals, Inc.
    • Ionis Pharmaceuticals
    • CSL
    • Attune Pharmaceuticals
    • Adverum Biotechnologies, Inc.
    • KalVista Pharmaceuticals, Inc.
    • Takeda Pharmaceutical Company Limited
    • Pharming
図表

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 North America hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 3 North America hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 4 North America hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 5 North America hereditary angioedema therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 6 U.S. hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 7 U.S. hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 8 U.S. hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 9 Canada hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 10 Canada hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 11 Canada hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 12 Europe hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 13 Europe hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 14 Europe hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 15 Europe hereditary angioedema therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 16 Germany hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 17 Germany hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 18 Germany hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 19 UK hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 20 UK hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 21 UK hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 22 France hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 23 France hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 24 France hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 25 Italy hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 26 Italy hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 27 Italy hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 28 Spain hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 29 Spain hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 30 Spain hereditary angioedema therapeutics market, by route of administration, (USD Million) 2018 - 2030
  • Table 31 Denmark hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 32 Denmark hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 33 Denmark hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 34 Sweden hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 35 Sweden hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 36 Sweden hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 37 Norway hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 38 Norway hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 39 Norway hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific hereditary angioedema therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 44 Japan hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 45 Japan hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 46 Japan hereditary angioedema therapeutics market, by route of administration, (USD Million) 2018 - 2030
  • Table 47 China hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 48 China hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 49 China hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 50 India hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 51 India hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 52 India hereditary angioedema therapeutics market, by route of administration, (USD Million) 2018 -2030
  • Table 53 Australia hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 54 Australia hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 55 Australia hereditary angioedema therapeutics market, by route of administration, (USD Million) 2018 -2030
  • Table 56 Thailand hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 57 Thailand hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 58 Thailand hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 59 South Korea hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 60 South Korea hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 61 South Korea hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 62 Latin America hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 63 Latin America hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 64 Latin America hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 65 Latin America hereditary angioedema therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 66 Brazil hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 67 Brazil hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 68 Brazil hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 69 Mexico hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 70 Mexico hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 71 Mexico hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 72 Argentina hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 73 Argentina hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 74 Argentina hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 75 Middle East and Africa hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 76 Middle East and Africa hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 77 Middle East and Africa hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 78 Middle East and Africa hereditary angioedema therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 79 South Africa hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 80 South Africa hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 81 South Africa hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 85 UAE hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 86 UAE hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 87 UAE hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 88 Kuwait hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 89 Kuwait hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 90 Kuwait hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Hereditary angioedema therapeutics: Market outlook
  • Fig. 9 Hereditary angioedema therapeutics: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Hereditary angioedema therapeutics market driver impact
  • Fig. 15 Hereditary angioedema therapeutics market restraint impact
  • Fig. 16 Hereditary angioedema therapeutics market strategic initiatives analysis
  • Fig. 17 Hereditary angioedema therapeutics market: Treatment movement analysis
  • Fig. 18 Hereditary angioedema therapeutics market: Treatment outlook and key takeaways
  • Fig. 19 C1-esterase inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Bradykinin B2 receptor antagonist market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Kallikrein inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Hereditary angioedema therapeutics market: End-use movement analysis
  • Fig. 24 Hereditary angioedema therapeutics market: End-use outlook and key takeaways
  • Fig. 25 Prophylaxis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 On-demand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Hereditary angioedema therapeutics market: Route of administration movement analysis
  • Fig. 28 Hereditary angioedema therapeutics market: Route of administration outlook and key takeaways
  • Fig. 29 Intravenous market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Subcutaneous market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Oral market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Global hereditary angioedema therapeutics market: Regional movement analysis
  • Fig. 33 Global hereditary angioedema therapeutics market: Regional outlook and key takeaways
  • Fig. 34 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Middle East and Africa. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
目次
Product Code: GVR-3-68038-156-6

Hereditary Angioedema Therapeutics Market Growth & Trends:

The global hereditary angioedema therapeutic market size is expected to reach USD 5.8 billion by 2030, according to a new report by Grand View Research, Inc.., exhibiting a 7.4% CAGR from 2023 to 2030. Growing initiatives by international patient organizations to improve awareness about hereditary angioedema (HAE) among patients and healthcare providers is likely to be a high impact rendering driver for the market.

Patient advocacy organizations affiliated to HAE International (HAEi) are focusing on campaigns through both print and social media in order to raise awareness levels for hereditary angioedema. HAEi has also introduced family testing tools for improving patient awareness levels, which is likely to help in providing accurate diagnosis and optimal medical treatment. Pharmaceutical and biotechnology companies such as CSL Limited, Pharming Group N.V., and Shire Plc. engaged in development of therapies for HAE have also lent their support and collaborated with the hereditary angioedema community so as to create effective diagnosis process and treatment for the condition.

Universities in different countries across the globe are collaborating with each other in order to develop new therapies for the management of hereditary angioedema attacks. For instance, in 2018, 26 universities from Europe, Australia, and Canada collaborated on an international study to develop a novel oral therapy for prevention of the condition.

Measures undertaken by countries for improving patient access to new therapies, along with modification in regulatory guidelines for facilitating faster drug review and approval for HAE, are expected to contribute to market growth. For instance, in July 2018, China's National Health Commission (NHC) and State Drug Administration (SDA) allowed pharmaceutical drug manufacturers to file for New Drug Application (NDA) for therapies for rare diseases whose treatment is currently not available in the country. The decision has allowed drug manufacturers to use clinical trial data from outside China while filing for NDA.

Hereditary Angioedema Therapeutics Market Report Highlights:

  • The C1-esterase inhibitor segment held the largest share in 2022 owing to high usage rates of the products in on-demand and prophylactic treatment of HAE
  • On-demand treatment accounted for the dominant share in the market and is expected to witness lucrative growth over the forecast period. Expected launch of products in new geographies is likely to be a key growth driver for the segment
  • North America dominated the overall hereditary angioedema therapeutics market in terms of revenue in 2022. Growing number of cases of the condition, favorable government programs, increasing awareness levels among patients, and presence of highly expert healthcare professionals are factors contributing to the major share of this regional market
  • Asia Pacific is expected to register lucrative growth over the forecast period owing to improving healthcare infrastructure and high unmet medical needs. Moreover, launch of new therapies for the treatment of the condition is likely to facilitate market growth in the region
  • Key players include Ionis Pharmaceuticals, Inc.; BioCryst Pharmaceuticals, Inc.; Pharming Group N.V.; CSL Limited; Shire plc; Adverum Biotechnologies, Inc.; Attune Pharmaceuticals, Inc.; and KalVista Pharmaceuticals, Inc.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Treatment
    • 1.1.2. End-use
    • 1.1.3. Route of administration
    • 1.1.4. Regional scope
    • 1.1.5. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Treatment outlook
    • 2.2.2. End-use outlook
    • 2.2.3. Route of administration outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Hereditary Angioedema Therapeutic Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Hereditary Angioedema Therapeutic Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. Hereditary Angioedema Therapeutic Market: Treatment Estimates & Trend Analysis

  • 4.1. Hereditary Angioedema Therapeutic Market: Key Takeaways
  • 4.2. Hereditary Angioedema Therapeutic Market: Movement & Market Share Analysis, 2022 & 2030
  • 4.3. C1-esterase Inhibitor
    • 4.3.1. C1-esterase inhibitor market estimates and forecasts, 2018 to 2030, (USD Million)
  • 4.4. Bradykinin B2 Receptor Antagonist
    • 4.4.1. Bradykinin B2 receptor antagonist market estimates and forecasts, 2018 to 2030, (USD Million)
  • 4.5. Kallikrein Inhibitor
    • 4.5.1. Kallikrein inhibitor market estimates and forecasts, 2018 to 2030, (USD Million)
  • 4.6. Others
    • 4.6.1. Others market estimates and forecasts, 2018 to 2030, (USD Million)

Chapter 5. Hereditary Angioedema Therapeutic Market: End-use Estimates & Trend Analysis

  • 5.1. Hereditary Angioedema Therapeutic Market: Key Takeaways
  • 5.2. Hereditary Angioedema Therapeutic Market: Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Prophylaxis
    • 5.3.1. Silicon market estimates and forecasts, 2018 to 2030, (USD Million)
  • 5.4. On-demand
    • 5.4.1. Metal market estimates and forecasts, 2018 to 2030, (USD Million)

Chapter 6. Hereditary Angioedema Therapeutic Market: Route of Administration Estimates & Trend Analysis

  • 6.1. Hereditary Angioedema Therapeutic Market: Key Takeaways
  • 6.2. Hereditary Angioedema Therapeutic Market: Movement & Market Share Analysis, 2022 & 2030
  • 6.3. Intravenous
    • 6.3.1. Intravenous market estimates and forecasts, 2018 to 2030, (USD Million)
  • 6.4. Subcutaneous
    • 6.4.1. Subcutaneous market estimates and forecasts, 2018 to 2030, (USD Million)
  • 6.5. Oral
    • 6.5.1. Oral market estimates and forecasts, 2018 to 2030, (USD Million)

Chapter 7. Hereditary Angioedema Therapeutic Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Outlook
  • 7.2. Hereditary Angioedema Therapeutic Market by Region: Key Takeaways
  • 7.3. North America
    • 7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.3.2. U.S.
      • 7.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.3.3. Canada
      • 7.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.3. France
      • 7.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.6. Sweden
      • 7.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.7. Norway
      • 7.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.2. China
      • 7.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.3. India
      • 7.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.5. Thailand
      • 7.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.6. South Korea
      • 7.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.6.2. Mexico
      • 7.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.6.3. Argentina
      • 7.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.7. MEA
    • 7.7.1. Saudi Arabia
      • 7.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.7.2. South Africa
      • 7.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Market Participant Categorization
    • 8.2.1. BioCryst Pharmaceuticals, Inc.
      • 8.2.1.1. Company overview
      • 8.2.1.2. Financial performance
      • 8.2.1.3. Product benchmarking
      • 8.2.1.4. Strategic initiatives
    • 8.2.2. Ionis Pharmaceuticals
      • 8.2.2.1. Company overview
      • 8.2.2.2. Financial performance
      • 8.2.2.3. Product benchmarking
      • 8.2.2.4. Strategic initiatives
    • 8.2.3. CSL
      • 8.2.3.1. Company overview
      • 8.2.3.2. Financial performance
      • 8.2.3.3. Product benchmarking
      • 8.2.3.4. Strategic initiatives
    • 8.2.4. Attune Pharmaceuticals
      • 8.2.4.1. Company overview
      • 8.2.4.2. Financial performance
      • 8.2.4.3. Product benchmarking
      • 8.2.4.4. Strategic initiatives
    • 8.2.5. Adverum Biotechnologies, Inc.
      • 8.2.5.1. Company overview
      • 8.2.5.2. Financial performance
      • 8.2.5.3. Product benchmarking
      • 8.2.5.4. Strategic initiatives
    • 8.2.6. KalVista Pharmaceuticals, Inc.
      • 8.2.6.1. Company overview
      • 8.2.6.2. Financial performance
      • 8.2.6.3. Product benchmarking
      • 8.2.6.4. Strategic initiatives
    • 8.2.7. Takeda Pharmaceutical Company Limited
      • 8.2.7.1. Company overview
      • 8.2.7.2. Financial performance
      • 8.2.7.3. Product benchmarking
      • 8.2.7.4. Strategic initiatives
    • 8.2.8. Pharming
      • 8.2.8.1. Company overview
      • 8.2.8.2. Financial performance
      • 8.2.8.3. Product benchmarking
      • 8.2.8.4. Strategic initiative